Gas6 as a putative noninvasive biomarker of hepatic fibrosis

Biomark Med. 2016 Dec;10(12):1241-1249. doi: 10.2217/bmm-2016-0210. Epub 2016 Dec 7.

Abstract

Aim: To evaluate serum growth arrest-specific gene 6 (Gas6) concentration as a biomarker of liver fibrosis progression.

Materials & methods: One hundred and thirteen consecutive patients affected by chronic liver disease underwent transient elastography, Gas6 measurement and, if clinically indicated, liver biopsy.

Results: Gas6 concentration was directly correlated to liver stiffness (r = 0.67; p < 0.0001) and was significantly higher in patients with advanced fibrosis (Ishak 4-5; p < 0.001). A plasma concentration <30 ng/ml Gas6 ruled out fibrosis with 84% sensitivity and 56% specificity, while values >42 ng/ml identified severe fibrosis with a sensitivity of 64% and a specificity of 95%; the diagnostic accuracy was comparable to that of transient elastography.

Conclusion: Gas6 is a novel biomarker of liver fibrosis, with a potential clinical and pathophysiological relevance.

Keywords: cirrhosis; fibrosis; growth arrest-specific gene 6 (Gas6); liver elastography; liver stiffness.

MeSH terms

  • Aged
  • Area Under Curve
  • Biomarkers / blood*
  • Elasticity Imaging Techniques
  • Female
  • Hepatitis B / complications
  • Hepatitis B / diagnosis
  • Hepatitis B / epidemiology
  • Hepatitis C / complications
  • Hepatitis C / diagnosis
  • Hepatitis C / epidemiology
  • Humans
  • Intercellular Signaling Peptides and Proteins / blood*
  • Liver / physiopathology
  • Liver Cirrhosis / diagnosis*
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Male
  • Middle Aged
  • ROC Curve
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • Intercellular Signaling Peptides and Proteins
  • growth arrest-specific protein 6